Observational analysis reveals that anemoside B4 reduces inflammation and ferroptosis in sepsis-induced acute lung injury, suggesting a novel therapeutic mechanism.
Key Points
Anemoside B4 significantly reduces lung injury and inflammation in sepsis-induced acute lung injury.
In vivo experiments showed decreased pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 following AB4 treatment.
Network pharmacology identified RAGE as a primary target of anemoside B4 in inhibiting ferroptosis.
Molecular docking confirmed a strong affinity between anemoside B4 and RAGE, suggesting direct interaction.